Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| ras Proteins | 13 | 2021 | 137 | 3.700 |
Why?
|
| Cell Membrane | 11 | 2020 | 676 | 3.050 |
Why?
|
| Molecular Dynamics Simulation | 10 | 2019 | 327 | 1.960 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 7 | 2024 | 185 | 1.700 |
Why?
|
| Lipid Bilayers | 5 | 2021 | 150 | 1.660 |
Why?
|
| Waist Circumference | 1 | 2026 | 26 | 0.940 |
Why?
|
| Thigh | 1 | 2026 | 42 | 0.930 |
Why?
|
| Protein Conformation | 6 | 2019 | 931 | 0.800 |
Why?
|
| Thoracostomy | 1 | 2020 | 10 | 0.650 |
Why?
|
| Hemothorax | 1 | 2020 | 11 | 0.650 |
Why?
|
| Chest Tubes | 1 | 2020 | 21 | 0.650 |
Why?
|
| Thoracic Injuries | 1 | 2020 | 42 | 0.630 |
Why?
|
| Genes, ras | 2 | 2018 | 97 | 0.600 |
Why?
|
| Protein Kinases | 1 | 2020 | 212 | 0.580 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2019 | 51 | 0.580 |
Why?
|
| Protein Domains | 2 | 2019 | 170 | 0.570 |
Why?
|
| Protein Multimerization | 2 | 2017 | 195 | 0.570 |
Why?
|
| Cardiovascular Diseases | 1 | 2026 | 822 | 0.560 |
Why?
|
| Catalytic Domain | 5 | 2020 | 165 | 0.550 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2016 | 18 | 0.480 |
Why?
|
| Neutrophils | 2 | 2017 | 346 | 0.440 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 221 | 0.440 |
Why?
|
| Models, Chemical | 1 | 2015 | 186 | 0.430 |
Why?
|
| Protein Binding | 6 | 2017 | 1561 | 0.400 |
Why?
|
| Computational Biology | 3 | 2017 | 618 | 0.380 |
Why?
|
| Trauma Centers | 4 | 2026 | 198 | 0.380 |
Why?
|
| Cholic Acid | 1 | 2012 | 8 | 0.370 |
Why?
|
| Phosphorylcholine | 1 | 2012 | 22 | 0.370 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 13 | 0.370 |
Why?
|
| Micelles | 1 | 2012 | 57 | 0.360 |
Why?
|
| Ibuprofen | 1 | 2012 | 35 | 0.360 |
Why?
|
| Phagocytosis | 1 | 2012 | 118 | 0.350 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 354 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 682 | 0.340 |
Why?
|
| Binding Sites | 4 | 2020 | 1160 | 0.320 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 255 | 0.310 |
Why?
|
| Lymphangitis | 1 | 2010 | 1 | 0.310 |
Why?
|
| Phosphatidylserines | 2 | 2021 | 21 | 0.310 |
Why?
|
| Mutation | 4 | 2024 | 4428 | 0.310 |
Why?
|
| Humans | 30 | 2026 | 98363 | 0.280 |
Why?
|
| Phosphorylation | 3 | 2020 | 1145 | 0.280 |
Why?
|
| Sepsis | 1 | 2012 | 402 | 0.270 |
Why?
|
| Mutation, Missense | 2 | 2019 | 309 | 0.250 |
Why?
|
| Guanosine Triphosphate | 3 | 2017 | 36 | 0.250 |
Why?
|
| Carcinoma | 1 | 2010 | 442 | 0.240 |
Why?
|
| Waist-Height Ratio | 1 | 2026 | 3 | 0.240 |
Why?
|
| Ligands | 4 | 2017 | 491 | 0.230 |
Why?
|
| Wounds, Penetrating | 1 | 2026 | 68 | 0.230 |
Why?
|
| Prospective Studies | 3 | 2026 | 4818 | 0.230 |
Why?
|
| Risk Assessment | 2 | 2026 | 2599 | 0.230 |
Why?
|
| Vascular System Injuries | 1 | 2026 | 49 | 0.230 |
Why?
|
| Models, Molecular | 4 | 2017 | 1396 | 0.220 |
Why?
|
| Nutrition Surveys | 1 | 2026 | 139 | 0.220 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2025 | 44 | 0.220 |
Why?
|
| Cause of Death | 1 | 2026 | 278 | 0.220 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 2381 | 0.210 |
Why?
|
| Vascular Surgical Procedures | 1 | 2026 | 170 | 0.210 |
Why?
|
| Injury Severity Score | 2 | 2026 | 167 | 0.210 |
Why?
|
| Vagina | 1 | 2025 | 187 | 0.200 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2025 | 186 | 0.190 |
Why?
|
| Adult | 9 | 2026 | 29587 | 0.180 |
Why?
|
| United States | 4 | 2026 | 8258 | 0.180 |
Why?
|
| Body Mass Index | 1 | 2026 | 867 | 0.180 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2021 | 10 | 0.180 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 2471 | 0.170 |
Why?
|
| Intestinal Perforation | 1 | 2021 | 39 | 0.170 |
Why?
|
| Middle Aged | 8 | 2026 | 29532 | 0.170 |
Why?
|
| Prenylation | 1 | 2021 | 3 | 0.170 |
Why?
|
| Predictive Value of Tests | 1 | 2026 | 1785 | 0.170 |
Why?
|
| Logistic Models | 3 | 2020 | 1276 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2013 | 146 | 0.160 |
Why?
|
| Cell Line | 3 | 2021 | 2483 | 0.160 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 140 | 0.150 |
Why?
|
| Male | 10 | 2026 | 47257 | 0.150 |
Why?
|
| Prognosis | 2 | 2026 | 4126 | 0.150 |
Why?
|
| Drainage | 1 | 2020 | 176 | 0.150 |
Why?
|
| Single Molecule Imaging | 1 | 2018 | 17 | 0.140 |
Why?
|
| Cricetulus | 1 | 2018 | 123 | 0.140 |
Why?
|
| Phosphatidylcholines | 1 | 2018 | 49 | 0.140 |
Why?
|
| Pneumonia | 1 | 2020 | 195 | 0.140 |
Why?
|
| Thrombectomy | 1 | 2021 | 265 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 264 | 0.140 |
Why?
|
| Wounds, Gunshot | 1 | 2021 | 154 | 0.140 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2018 | 102 | 0.140 |
Why?
|
| Firearms | 1 | 2019 | 91 | 0.140 |
Why?
|
| Cricetinae | 1 | 2018 | 533 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1009 | 0.130 |
Why?
|
| Female | 10 | 2026 | 51756 | 0.130 |
Why?
|
| Thoracotomy | 1 | 2018 | 71 | 0.130 |
Why?
|
| Protein Isoforms | 1 | 2019 | 304 | 0.130 |
Why?
|
| Nanostructures | 1 | 2018 | 93 | 0.130 |
Why?
|
| Stents | 1 | 2021 | 440 | 0.130 |
Why?
|
| Leukocyte Count | 1 | 2017 | 215 | 0.130 |
Why?
|
| Cyclic GMP-Dependent Protein Kinase Type II | 1 | 2016 | 2 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2678 | 0.120 |
Why?
|
| Occupational Exposure | 1 | 2018 | 100 | 0.120 |
Why?
|
| Time Factors | 1 | 2026 | 5576 | 0.120 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 87 | 0.120 |
Why?
|
| Length of Stay | 1 | 2020 | 876 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 84 | 0.120 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 73 | 0.120 |
Why?
|
| Allosteric Site | 2 | 2015 | 24 | 0.120 |
Why?
|
| Anions | 1 | 2016 | 33 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 642 | 0.120 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 2008 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 533 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2017 | 296 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2017 | 461 | 0.110 |
Why?
|
| Algorithms | 2 | 2015 | 2003 | 0.110 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 80 | 0.110 |
Why?
|
| Molecular Probes | 1 | 2015 | 38 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 547 | 0.110 |
Why?
|
| Software | 2 | 2015 | 697 | 0.100 |
Why?
|
| Mutant Proteins | 3 | 2021 | 99 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 341 | 0.100 |
Why?
|
| Animals | 5 | 2021 | 28981 | 0.100 |
Why?
|
| Aged | 4 | 2026 | 21844 | 0.100 |
Why?
|
| Critical Illness | 2 | 2017 | 361 | 0.100 |
Why?
|
| Solutions | 1 | 2013 | 84 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 622 | 0.100 |
Why?
|
| Signal Transduction | 4 | 2024 | 3633 | 0.090 |
Why?
|
| Peritoneal Lavage | 1 | 2012 | 12 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2026 | 9770 | 0.090 |
Why?
|
| Sampling Studies | 1 | 2012 | 75 | 0.090 |
Why?
|
| Physicians | 1 | 2019 | 685 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 1 | 2012 | 244 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2012 | 65 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2012 | 136 | 0.090 |
Why?
|
| Bile Acids and Salts | 1 | 2012 | 78 | 0.090 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 256 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 115 | 0.090 |
Why?
|
| Nucleotides | 1 | 2012 | 93 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2012 | 150 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 271 | 0.090 |
Why?
|
| Computer Simulation | 2 | 2015 | 1147 | 0.090 |
Why?
|
| Reference Values | 1 | 2012 | 608 | 0.080 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2011 | 26 | 0.080 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 40 | 0.080 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2011 | 29 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2012 | 722 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 890 | 0.080 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 531 | 0.080 |
Why?
|
| Water | 1 | 2012 | 309 | 0.080 |
Why?
|
| Iopamidol | 1 | 2010 | 9 | 0.080 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 156 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2012 | 970 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 214 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2012 | 602 | 0.070 |
Why?
|
| Radiography | 1 | 2010 | 763 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1178 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2858 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 2085 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 828 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 7418 | 0.060 |
Why?
|
| Inflammation | 1 | 2012 | 1133 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1945 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1539 | 0.060 |
Why?
|
| Heart Failure | 1 | 2016 | 1502 | 0.050 |
Why?
|
| Neoplasms | 2 | 2019 | 3348 | 0.050 |
Why?
|
| Contrast Media | 1 | 2010 | 1013 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 2896 | 0.050 |
Why?
|
| Lipids | 2 | 2016 | 295 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2017 | 523 | 0.050 |
Why?
|
| Gastroenterostomy | 1 | 2021 | 7 | 0.040 |
Why?
|
| Endosonography | 1 | 2021 | 103 | 0.040 |
Why?
|
| Static Electricity | 1 | 2021 | 101 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2026 | 11039 | 0.040 |
Why?
|
| Registries | 1 | 2026 | 1127 | 0.040 |
Why?
|
| Politics | 1 | 2019 | 54 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 190 | 0.040 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2019 | 65 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 86 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 376 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2025 | 795 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2021 | 218 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 335 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 667 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 99 | 0.030 |
Why?
|
| Health Surveys | 1 | 2018 | 254 | 0.030 |
Why?
|
| Neoprene | 1 | 2016 | 1 | 0.030 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2016 | 23 | 0.030 |
Why?
|
| Sildenafil Citrate | 1 | 2016 | 24 | 0.030 |
Why?
|
| Serine | 1 | 2016 | 106 | 0.030 |
Why?
|
| Hominidae | 1 | 2017 | 110 | 0.030 |
Why?
|
| Chicago | 1 | 2021 | 1519 | 0.030 |
Why?
|
| Endocytosis | 1 | 2016 | 187 | 0.030 |
Why?
|
| Dogs | 1 | 2016 | 642 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 257 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2015 | 59 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2016 | 286 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 907 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 793 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 83 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 923 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 124 | 0.030 |
Why?
|
| Adolescent | 2 | 2021 | 10137 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1397 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 2021 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1791 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 988 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 425 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 402 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 6271 | 0.020 |
Why?
|